Barraud Damien, Faivre Valérie, Damy Thibault, Welschbillig Stéphane, Gayat Etienne, Heymes Christophe, Payen Didier, Shah Ajay M, Mebazaa Alexandre
Equipe d'Accueil 322, Université, Paris, France.
Crit Care Med. 2007 May;35(5):1376-82. doi: 10.1097/01.CCM.0000261889.18102.84.
Current treatment strategies for severe septic conditions (i.e., intravenous fluids, vasopressors, and cardiac inotropes) reestablish fluid balance and improve cardiac systole but do not address diastolic dysfunction. Our study aimed to fully characterize both systolic and diastolic abnormalities of sepsis-associated heart failure and to identify treatment that would support full-cycle cardiac improvement.
Endotoxin-injected rabbits, an animal model of abnormal cardiac function in human sepsis, were used to delineate cardiac abnormalities and to examine effects of drug treatments on heart systolic and diastolic function (n = 30); saline-injected animals served as comparators (n = 17). As treatment, three inotropes commonly used for treatment of cardiac failure were infused for 45 mins in separate animal groups-milrinone, dobutamine, and levosimendan.
Variables of left ventricular systolic and diastolic function were assessed with a pressure conductance catheter. Measurements were made before and after endotoxin/saline injection and before and after inotrope treatment.
Pressure-volume analyses of the left ventricle showed marked impairment in systolic function and in all indices of diastolic function (isovolumic relaxation time constant, left ventricular end-diastolic pressure, and end-diastolic pressure-volume relationship) in endotoxin-treated rabbits. The inotropes, milrinone, dobutamine, and levosimendan, could each partially or completely restore systolic function in the lipopolysaccharide-treated rabbits. However, only levosimendan therapy led to additional beneficial effects on left ventricular relaxation and diastolic function.
Cardiac failure in severe sepsis results from impairments in both systolic and diastolic functions. Treatment with the calcium sensitizer levosimendan improved both systolic and diastolic cardiac functions in septic animals, but cyclic adenosine monophosphate-dependent inotropes milrinone and dobutamine only improved systolic function.
目前针对严重脓毒症的治疗策略(即静脉输液、血管升压药和强心药)可重建液体平衡并改善心脏收缩功能,但无法解决舒张功能障碍问题。我们的研究旨在全面描述脓毒症相关性心力衰竭的收缩和舒张异常,并确定能够支持心脏全周期改善的治疗方法。
使用注射内毒素的兔子,这是一种人类脓毒症中心脏功能异常的动物模型,用于描绘心脏异常情况并检查药物治疗对心脏收缩和舒张功能的影响(n = 30);注射生理盐水的动物作为对照(n = 17)。作为治疗手段,在不同动物组中分别输注三种常用于治疗心力衰竭的强心药45分钟——米力农、多巴酚丁胺和左西孟旦。
使用压力导丝导管评估左心室收缩和舒张功能的各项指标。在内毒素/生理盐水注射前后以及强心药治疗前后进行测量。
左心室压力-容积分析显示,在内毒素处理的兔子中,收缩功能以及舒张功能的所有指标(等容舒张时间常数、左心室舒张末期压力和舒张末期压力-容积关系)均有明显受损。强心药米力农、多巴酚丁胺和左西孟旦均可部分或完全恢复脂多糖处理兔子的收缩功能。然而,只有左西孟旦治疗对左心室舒张和舒张功能产生了额外的有益影响。
严重脓毒症中的心力衰竭是由收缩和舒张功能受损共同导致的。钙增敏剂左西孟旦治疗可改善脓毒症动物的收缩和舒张心脏功能,但依赖环磷酸腺苷的强心药米力农和多巴酚丁胺仅改善了收缩功能。